NSCLC
Therefore, we suggest that IL-6R is both a viable target for the development of CSC-directed lung cancer therapeutics and a potential CSC marker in NSCLC.
Therefore, we suggest that <span class="gene" id="22552503-12-27-32">IL-6R</span> is both a viable target for the development of CSC-directed lung cancer therapeutics and a potential CSC marker in <span class="disease" id="22552503-12-148-153">NSCLC</span>.